Literature DB >> 7451983

Further studies of the human platelet receptor for quinine- and quinine-dependent antibodies.

T J Kunicki, N Russell, A T Nurden, R H Aster, J P Caen.   

Abstract

Previous studies have shown that the receptor for quinine- and quinidine-dependent antibodies is not expressed on the surface of platelets from patients with the Bernard-Soulier (B-S) syndrome. We now report data to suggest that these platelets lack the receptor for these antibodies. Since B-S platelets are also missing 2 related components of the GP I complex, GP lb and glycocalicin, our findings suggest that the receptor for quinine- and quinidine-dependent antibodies may be associated with this complex on normal platelets. An antibody previously shown to be directed against a surface antigen that migrated in the GP I position on SDS-polyacrylamide gel electrophoresis specifically blocked the reaction of the receptor with quinine- or quinidine-dependent antibodies. Purified glycocalicin, however, lacked detectable receptor activity. In contrast, a mixture of GP lb and a putative structural analog of this glycoprotein (Mr 210,000) eluted from wheat germ affinity columns after chromatography of Triton X soluble preparations of platelets or membranes was shown to contain at least 80% of the total receptor activity. Our results strongly suggest that the receptor is associated with GP lb and/or its high m.w. structural analog(s).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7451983

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies.

Authors:  F H Claas
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA.

Authors:  Julie A Peterson; Tamara N Nelson; Adam J Kanack; Richard H Aster
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

3.  Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent.

Authors:  M E Smith; D M Reid; C E Jones; J V Jordan; C A Kautz; N R Shulman
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

4.  Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.

Authors:  R B Stricker; P T Reyes; L Corash; M A Shuman
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

5.  Platelet surface antigens: analysis by monoclonal antibodies. I. Antibodies. I. Immunological and biochemical studies.

Authors:  S Santoso; J Lohmeyer; H Rennich; K J Clemetson; C Mueller-Eckhardt
Journal:  Blut       Date:  1984-03

Review 6.  Haematological effects of non-narcotic analgesics.

Authors:  P A Miescher; W Pola
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Surface modifications in the platelets of a patient with alpha-N-acetyl-D-galactosamine residues, the Tn-syndrome.

Authors:  A T Nurden; D Dupuis; D Pidard; N Kieffer; T J Kunicki; J P Cartron
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

Review 8.  Drug-induced thrombocytopenia.

Authors:  Gian Paolo Visentin; Chao Yan Liu
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

9.  Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes.

Authors:  S I Rosenfeld; R J Looney; J P Leddy; D C Phipps; G N Abraham; C L Anderson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

10.  Acquired Bernard-Soulier syndrome. Evidence for the role of a 210,000-molecular weight protein in the interaction of platelets with von Willebrand factor.

Authors:  R B Stricker; D Wong; S R Saks; L Corash; M A Shuman
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.